The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
BeiGene AUS Pty Ltd
Regulatory activities for this sponsor.
Loading...
Sponsor content
7 result(s) found, displaying 1 to 7
-
Australian Public Assessment Report (AusPAR)Brukinsa (zanubritinib) was approved to treat adult patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma, including patients with deletion 17p and/or TP53 mutation.
-
Australian Public Assessment Report (AusPAR)Tevimbra (tislelizumab) has been approved for the treatment of oesophageal squamous cell carcinoma and non-small cell lung cancer.
-
-
Australian Public Assessment Report (AusPAR)Brukinsa (zanubrutinib) for the treatment of adult patients with mantle cell lymphoma
-
Australian Public Assessment Report (AusPAR)Brukinsa (zanubrutinib) for the treatment of of adult patients with Waldenström’s macroglobulinaemia
-
-